FDA Orphan Drug Designation and completion of FDA INTERACT meeting for BVX001 in the treatment of AML announced April 23, 2024
Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression April 16, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
First Patient dosed in the RIVER-52 Ph 2 Study of RVU120 for the Treatment of Patients with R/R AML and HR-MDS February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) January 23, 2024
Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML January 10, 2024
Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed January 10, 2024
FDA Clears IND Application for SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML January 4, 2024
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
